Consistent with a previous study, we found that treatment of DLBCL cells with LAQ824 also results in an increase in human leukocyte antigen (HLA)‐A expression, which extends the rational basis for using HDACis in combinatorial therapy. This evidence concerns the gene HLA-A and diffuse large B-cell lymphoma.